{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:45:39Z","timestamp":1785789939583,"version":"3.56.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["RETINA"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1097\/00006982-200302000-00003","type":"journal-article","created":{"date-parts":[[2004,9,3]],"date-time":"2004-09-03T03:50:50Z","timestamp":1094183450000},"page":"14-23","source":"Crossref","is-referenced-by-count":70,"title":["ANECORTAVE ACETATE AS MONOTHERAPY FOR THE TREATMENT OF SUBFOVEAL LESIONS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD)"],"prefix":"10.1097","volume":"23","author":[{"name":"The Anecortave Acetate Clinical Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-3-20160304","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","author":"","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R3-3-20160304","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","volume":"22","author":"","year":"2002","journal-title":"Retina"},{"key":"R4-3-20160304","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","volume":"120","author":"Krzystolik","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R6-3-20160304","first-page":"283","volume":"42","author":"Penn","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-3-20160304","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9394(14)70868-2","volume":"124","author":"Casey","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"R8-3-20160304","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1517\/13543784.6.12.1867","volume":"6","author":"Clark","year":"1997","journal-title":"Exp Opin Invest Drugs"},{"key":"R9-3-20160304","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/jop.1999.15.413","volume":"15","author":"McNatt","year":"1999","journal-title":"J Ocular Pharm Therap"},{"key":"R10-3-20160304","first-page":"1954","volume":"38","author":"BenEzra","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-3-20160304","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archopht.1991.01080090044025","volume":"109","author":"","year":"1991","journal-title":"Arch Ophthalmol"}],"container-title":["RETINA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-200302000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:45:16Z","timestamp":1785786316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200302000-00003"}},"subtitle":["Interim (Month 6) Analysis of Clinical Safety and Efficacy"],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":9,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1097\/00006982-200302000-00003","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}